| http://www.w3.org/ns/prov#value | - However, given that pathways other than VEGF or mTOR play a role in tumorigenesis,57 other pathways may also be related to resistance to VEGF or mTOR-targeted therapy in RCC. For instance, basic fibroblast growth factor, hepatocyte growth factor, and IL-6 have recently been shown to increase or remain high immediately before progress
|
